Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL after the RNC : Severe storms moving south, but more rain is on the way. How long we have to deal with heavy rain and flooding
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crispr Therapeutics Ag
(NQ:
CRSP
)
56.21
-4.27 (-7.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crispr Therapeutics Ag
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus
July 02, 2021
The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped.
Via
Investor's Business Daily
Topics
Initial Public Offering
Stocks
Exposures
Fossil Fuels
Securities Market
US Equities
Here's What Drove Gene Editing Stocks Higher This Week
July 02, 2021
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
Via
The Motley Fool
'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond
June 30, 2021
Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns...
Via
Benzinga
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
June 30, 2021
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.
Via
InvestorPlace
Why Gene Editing Stocks Are Trading Higher Again Today
June 30, 2021
Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...
Via
Benzinga
60 Biggest Movers From Yesterday
June 29, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...
Via
Benzinga
44 Stocks Moving In Monday's Mid-Day Session
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...
Via
Benzinga
Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR
June 28, 2021
Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high.
Via
Investor's Business Daily
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
June 28, 2021
Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics.
Via
InvestorPlace
24 Stocks Moving in Monday's Pre-Market Session
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...
Via
Benzinga
Crispr Therapeutics Stock Sees Improved Relative Strength Rating
June 25, 2021
Crispr Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 68 to 74.
Via
Investor's Business Daily
Gold Stocks On Sale
June 20, 2021
In this video, we discuss our top stocks of the week, how gold is on sale, and how some market signals have been particularly troubling and misread.
Via
Talk Markets
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
June 18, 2021
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap...
Via
Talk Markets
Cramer Gives His Opinion On Bank of America, Advanced Micro Devices And More
June 17, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said Martin Marietta Materials, Inc. (NYSE: MLM) is a well-run company. He likes the stock because it doesn't...
Via
Benzinga
CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases
June 15, 2021
CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a...
Via
Benzinga
Can Vertex Pharmaceuticals Recover From Its Latest Setback?
June 15, 2021
Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately.
Via
The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
June 15, 2021
This biotech has likely reached its peak potential, for now.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021
June 14, 2021
Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,...
Via
Benzinga
10 Biggest Price Target Changes For Monday
June 14, 2021
Needham raised OrthoPediatrics Corp. (NASDAQ: KIDS) price target from $70 to $77. Vertex Pharmaceuticals shares rose 0.2% to close at $63.51 on Friday. HC Wainwright & Co....
Via
Benzinga
Why Crispr's Gene-Editing Jump Wasn't Enough To Help Vertex Stock
June 11, 2021
Vertex Pharmaceuticals and Crispr Therapeutics appeared Friday to be making progress on a cure for two blood diseases. But only CRSP stock popped.
Via
Investor's Business Daily
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials
June 11, 2021
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials...
Via
Benzinga
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
June 11, 2021
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
June 07, 2021
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...
Via
Benzinga
Exposures
Product Safety
What's the Best Way to Invest in Genetics Stocks?
June 07, 2021
Here are some of our experts' favorite gene editing plays for the long run.
Via
The Motley Fool
How Much Will the Nkarta Deal Help CRISPR Therapeutics?
June 06, 2021
Unfortunately, this isn't an endorsement by a big drug developer.
Via
The Motley Fool
1 Genetics Stock to Put on Your Radar
June 04, 2021
Some of our experts think this stock has tons of long-term potential.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Cathie Wood's Ark Loads Up Further On Tesla And Cuts Apple Stake
May 19, 2021
Cathie Wood-led Ark Investment Management on Tuesday snapped up $27.2 million worth of shares in Tesla Inc (NASDAQ: TSLA) after a two-week gap during which shares of the...
Via
Benzinga
3 Healthcare Stocks That Might Soar if Biden Gets This Part of His Budget Approved
May 12, 2021
A new agency could help fund the attack on this chronic disease.
Via
The Motley Fool
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat
May 12, 2021
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics...
Via
Benzinga
ARKK Stocks Breakdowns and Bounces
May 07, 2021
After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today.
Via
Talk Markets
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.